Kymera Results Presentation Deck

Interim Safety Data Summary Dose Level 1 • 4 patients at Dose Level 1 (DL1, 0.05 mg/kg) ● ● All 4 patients heavily pretreated (≥3 prior lines) 3 solid tumor 1 CTCL No DLTS, no treatment-related SAEs, no AEs leading to discontinuation KYMERA ©2022 KYMERA THERAPEUTICS, INC. PAGE 11

View entire presentation